Liu Y, et al. - Researchers determined what markers were predictive of benefit with regorafenib (Rego) for progression-free survival (PFS) in metastatic colorectal cancer. For both PFS and overall survival (OS), baseline levels of multiple markers (including HGF, IL-6, PlGF, VEGF-R1, OPN) were prognostic, but VCAM-1, OPN, and PDGF-AA were the best potentially predictive biomarkers associated with PFS, where a lower hazard was noted for patients receiving Rego. Candidate prognostic markers have been identified as key factors for VEGF biology, including PlGF and VEGF-R1. Biomarker changes seen here can provide insights into combinatio strategies with Rego for future studies.